Fact CheckerSign in

NCT07555301Not yet recruiting

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Source: ClinicalTrials.gov · Last updated 29 Apr 2026

Brief summary (registry, in English)

An observational study tracking the clinical course of patients with IgA nephropathy.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
50 (estimated)
First submitted
21 Apr 2026
Start date
1 Jun 2026
Primary completion date
31 Dec 2028
Lead sponsor
Waid City Hospital, Zurich
NCT number
NCT07555301

What you commit to

  • Study type: Observational
  • Planned participants: 50
  • From 1 Jun 2026 to the primary completion date, 31 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • age \< 18y

Who the study is looking for

  • IgA Nephropathy, Use of Sparsentan

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Stadtspital Zürich
Coordinator of this site? Confirm its status
ZurichSwitzerlandUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.